Yesterday, Alex Philippidis at Genetic Engineering and Biotechnology News released their annual ranking of the top 10 U.S. biopharma clusters. To rank the clusers, five criteria are considered: NIH funding, venture capital funding, number of biotech patents awarded, lab space, and jobs.
Landing the number 6 spot is the Greater Philadelphia region, home to this year’s BIO International Convention. From the report:
The birthplace of independence saw a nice year-over-year increase in venture capital financing, leaping almost 30% over 2013 to $211.376 million in 23 deals last year, good enough for fifth on this year’s VC rankings. It’s the strongest sign yet that it has made progress in evolving from a heritage pharma mecca to a more diverse concentration of biopharma businesses and institutions (including 25 medical schools). Philadelphia’s University City Science Center has long been an anchor for regional biopharma; in October it won a $1 million grant from the U.S. Economic Development Administration for a second commercialization program, Phase 1 Ventures. The region is also fifth in jobs (48,874 according to JLL), but seventh in patents (1,195) and lab space (6.62 million square feet), as well as eighth in NIH funding ($87.596 million).
Register today if you’d like to join us in Philly this June. Don’t wait too long – early bird ends April 23.